MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze SUPN →
    • FindStock Picks / Stock Screener
    • Value · SUPNIntrinsic Value Calculator
    • Invest · SUPNInvestment Case
    • Hold · SUPN5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
SUPN stock logo

SUPN

Supernus Pharmaceuticals, Inc.

$28.15
0
 (0%)
Exchange:  NASDAQ
Market Cap:  1.639B
Shares Outstanding:  125M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – Specialty & GenericView industry performance
   
CEO:  Jack A. Khattar
Full Time Employees:  778
Address: 
9715 Key West Avenue
Rockville
MD
20850
US
Website:  https://www.supernus.com
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson’s Disease (PD) patients, APOKYN offers acute, intermittent relief during “off” episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson’s disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.

Click to read more…

Revenue Segmentation

Revenue by type

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
SUSUPN logoSUPNSupernus Pharmaceuticals, Inc.1.6B—10.2-2.7%
ALALVO logoALVOAlvotech1.6B——3.6%
ANANIP logoANIPANI Pharmaceuticals, Inc.1.7B14.97.89.3%
PAPAHC logoPAHCPhibro Animal Health Corporation1.5B15.812.311.8%
ETETON logoETONEton Pharmaceuticals, Inc.1.5B11246.720.4%
PCPCRX logoPCRXPacira BioSciences, Inc.1.5B10312.61.4%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/05 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,093,0001,188,0001,239,000
Gross Profit919,000957,000993,000
EBITDA-99,00083,000304,000
Operating Income-156,00032,000265,000
Net Income-129,0002,000210,000

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets1,277,6731,368,0731,452,648,000
Total Liabilities356,157332,340390,934,000
Total Stockholders Equity921,5161,035,7331,061,714,000
Total Debt41,52734,27130,365,000
Cash and Cash Equivalents75,05469,331128,448,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow111,085171,95147,331
Capital Expenditure-551-725-1,338
Free Cash Flow110,534171,22645,993
Net Income1,31673,865-38,550
Net Change in Cash-18,066-5,72360,567

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)2,111,283.186Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)2,161,598.431Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)2,137,034.500Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)466,663.986Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)480,155.867Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)473,569.297Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)325,065.969Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)335,173.545Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)330,239.151Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,193,887.954Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)1,222,340.207Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,208,449.801Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)5.850Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)5.940Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)5.760Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)1Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
661.817M  ?P/S
 (TTM)
: 
2.82
?Net Income
 (TTM)
: 
73.865M  ?P/E
 (TTM)
: 
-55.06
?Enterprise Value
 (TTM)
: 
2.302B  ?EV/FCF
 (TTM)
: 
26.47
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-4.15%  ?ROIC
 (TTM)
: 
-2.72%
?Net Debt
 (TTM)
: 
-419.341M  ?Debt/Equity
 (TTM)
: 
0.03
?P/B
 (TTM)
: 
2.3  ?Current Ratio
 (TTM)
: 
2.49

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
10.16Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates SUPN intrinsic value between $46.68 – $61.78 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate SUPN Intrinsic Value

Common questions about SUPN valuation

Is Supernus, Inc. (SUPN) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Supernus, Inc. (SUPN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is SUPN a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether SUPN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is SUPN’s P/E ratio?

You can see SUPN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for SUPN?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is SUPN a good long-term investment?

Whether SUPN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Supernus, Inc.

  • Supernus, Inc. intrinsic value calculatorEstimate what the business is worth
  • Supernus, Inc. 5-year outlookWhat has to go right, and what could go wrong
SUPN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0
MarketSnap

Trading Metrics:

Open: 28.35   Previous Close: 28.15
Day Low: 27.97   Day High: 31.62
Year Low: 27.97   Year High: 59.68
Price Avg 50: 42.42   Price Avg 200: 47.25
Volume: 9.053M   Average Volume: 898745

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Supernus Pharmaceuticals Q3 Earnings Call Highlights
29-10-2026 18:16
Supernus Pharmaceuticals Q3 Earnings Call Highlights
Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript
29-10-2026 17:23
Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript
Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600
28-10-2026 17:43
Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600
Is Supernus Pharmaceuticals Inc (SUPN) a Bargain After 3.3% Drop? GF Value Says Undervalued
23-10-2026 19:56
Is Supernus Pharmaceuticals Inc (SUPN) a Bargain After 3.3% Drop? GF Value Says Undervalued
Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse Takeover
16-10-2026 09:41
Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse Takeover
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
24-09-2026 17:16
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze SUPN →
    • FindStock Picks / Stock Screener
    • Value · SUPNIntrinsic Value Calculator
    • Invest · SUPNInvestment Case
    • Hold · SUPN5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read